Michael H. Rabinowitz

1.5k citations

29 papers · 1.1k indexed · h-index 17

Co-authors: Larry E. Overman Paul A. Renhowe Steven W. Goldstein Hariharan Venkatesan Mark D. Rosen Leslie A. Robinson Terrance D. Barrett Nigel P. Shankley
Topics: Cancer, Hypoxia, and Metabolism (8 papers)Neuropeptides and Animal Physiology (4 papers)Metabolomics and Mass Spectrometry Studies (3 papers)
Cited by: Organic Chemistry Cancer Research Biotechnology
Journals: Journal of the American Chemical Society Journal of Medicinal Chemistry Journal of Pharmacology and Experimental Therapeutics
Partner nations: United States Belgium United Kingdom

In The Last Decade

Michael H. Rabinowitz

28 papers receiving 1.0k citations

Peers

Countries citing papers authored by Michael H. Rabinowitz

Since Specialization

Citations

This map shows the geographic impact of Michael H. Rabinowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael H. Rabinowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael H. Rabinowitz more than expected).

Fields of papers citing papers by Michael H. Rabinowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael H. Rabinowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael H. Rabinowitz. The network helps show where Michael H. Rabinowitz may publish in the future.

Co-authorship network of co-authors of Michael H. Rabinowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Michael H. Rabinowitz. A scholar is included among the top collaborators of Michael H. Rabinowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael H. Rabinowitz. Michael H. Rabinowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents 2023 ·Toxicologic Pathology ·(unknown),Debie J. Hoivik,Michael H. Rabinowitz	0
2	Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia 2022 ·Journal of Pharmacology and Experimental Therapeutics ·Anna Żuk,Zhihai Si,(unknown),(unknown),Debie J. Hoivik,Sanjay Danthi,(unknown),Vilmos Csizmadia,Michael H. Rabinowitz	17
3	Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2 2019 ·ACS Omega ·Scott D. Bembenek,Hariharan Venkatesan,Hillary M. Peltier,Mark D. Rosen,Terrance D. Barrett,Kimon C. Kanelakis,(unknown),(unknown),Taraneh Mirzadegan,Michael H. Rabinowitz	6
4	Physiological Control of Nitric Oxide in Neuronal BACE1 Translation by Heme-Regulated eIF2α Kinase HRI Induces Synaptogenesis 2015 ·Antioxidants and Redox Signaling ·Gerard ILL‐Raga,Marta Tajes,Arnau Busquets-García,Eva Ramos‐Fernández,Lina Moitoso de Vargas,Mònica Bosch-Morató,Biuse Guivernau,Victòria Valls-Comamala,Abel Eraso‐Pichot,Francesc X. Guix,César Fandos,Mark D. Rosen,Michael H. Rabinowitz,Rafaël Maldonado,Alejandra Álvarez,Andrés Ozaita,Francisco J. Muñoz	27
5	Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation‐induced anaemia in rats 2015 ·British Journal of Pharmacology ·Terrance D. Barrett,(unknown),(unknown),Kimon C. Kanelakis,Xiaodong Wu,Wen Yan,(unknown),Freddy Schoetens,Ying Jing,(unknown),Jingjin Gao,Da‐Thao Tran,Hariharan Venkatesan,Mark D. Rosen,Nigel P. Shankley,Michael H. Rabinowitz	42
6	JNJ-26070109 [(R)4-Bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: A Novel, Potent, and Selective Cholecystokinin 2 Receptor Antagonist with Good Oral Bioavailability 2011 ·Journal of Pharmacology and Experimental Therapeutics ·Magda F. Morton,Terrance D. Barrett,Jamie Freedman,Lina Li,Michèle Rizzolio,C Prendergast,Xiaodong Wu,Veronica Moreno,Jayashree Pyati,Katherine W. Figueroa,Laurence Cagnon,Guy Lagaud,Luc Ver Donck,(unknown),Brett D. Allison,Michael H. Rabinowitz,Nigel P. Shankley	5
7	Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor 2011 ·Molecular Pharmacology ·Terrance D. Barrett,(unknown),(unknown),Kimon C. Kanelakis,Xiaodong Wu,(unknown),Wen Yan,Andrew Young,(unknown),(unknown),Da‐Thao Tran,Hariharan Venkatesan,Mark D. Rosen,Hillary M. Peltier,(unknown),Michèle Rizzolio,Scott D. Bembenek,Tara Mirzadegan,Michael H. Rabinowitz,Nigel P. Shankley	65
8	A One-Step Synthesis of 2,4-Unsubstituted Quinoline-3-carboxylic Acid Esters from o-Nitrobenzaldehydes 2010 ·The Journal of Organic Chemistry ·Hariharan Venkatesan,(unknown),Todd K. Jones,Michael H. Rabinowitz	41
9	Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: Tuning of receptor selectivity and in vivo efficacy 2009 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),Hariharan Venkatesan,(unknown),Wen Yan,Terrance D. Barrett,Guy Lagaud,Lina Li,Magda F. Morton,C Prendergast,Xiaodong Wu,Nigel P. Shankley,Michael H. Rabinowitz	13
10	Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2α (HRI) kinase 2009 ·Bioorganic & Medicinal Chemistry Letters ·Mark D. Rosen,Craig R. Woods,Steven D. Goldberg,Michael D. Hack,(unknown),Young Chul Yang,Pamela C. Wagaman,(unknown),(unknown),Terrance D. Barrett,Kimon C. Kanelakis,Jui Yoa Chang,Nigel P. Shankley,Michael H. Rabinowitz	34
11	Characterization of a Robust Enzymatic Assay for Inhibitors of 2-Oxoglutarate-Dependent Hydroxylases 2009 ·SLAS DISCOVERY ·Kimon C. Kanelakis,(unknown),Lina Li,Jiejun Wu,Wen Yan,Mark D. Rosen,Michèle Rizzolio,Meghana V. Trivedi,Magda F. Morton,Young Chul Yang,Hariharan Venkatesan,Michael H. Rabinowitz,Nigel P. Shankley,Terrance D. Barrett	13
12	Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: Discovery of CCKR1 selectivity in a previously CCKR2-selective lead series 2009 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Brett D. Allison,(unknown),Lina Li,Magda F. Morton,C Prendergast,Xiaodong Wu,Nigel P. Shankley,Michael H. Rabinowitz	10
13	Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands 2007 ·Bioorganic & Medicinal Chemistry Letters ·Craig R. Woods,Michael D. Hack,Brett D. Allison,(unknown),Mark D. Rosen,Magda F. Morton,C Prendergast,Terrance D. Barrett,Nigel P. Shankley,Michael H. Rabinowitz	8
14	Hantzsch Synthesis of Pyrazolo[1‘,2‘:1,2]pyrazolo[3,4-b]pyridines: Partial Agonists of the Calcitonin Receptor 2005 ·The Journal of Organic Chemistry ·Eric E. Boros,David J. Cowan,Richard F. Cox,(unknown),Michael H. Rabinowitz,James B. Thompson,(unknown)	13
15	Design of Selective and Soluble Inhibitors of Tumor Necrosis Factor-α Converting Enzyme (TACE) 2001 ·Journal of Medicinal Chemistry ·Michael H. Rabinowitz,Robert Andrews,J. David Becherer,D. Mark Bickett,(unknown),James G. Conway,David J. Cowan,Micheal D. Gaul,(unknown),Millard H. Lambert,M. Anthony Leesnitzer,Darryl McDougald,Marcia L. Moss,David L. Musso,Michèle Rizzolio	57
16	Solid-phase/solution-phase combinatorial synthesis of neuroimmunophilin ligands 2000 ·Bioorganic & Medicinal Chemistry Letters ·Michael H. Rabinowitz,Pierfausto Seneci,Tino Rossi,(unknown),Martyn J. Deal,Georg C. Terstappen	14
17	Efficient Total Syntheses of Pumiliotoxins A and B. Applications of Iodide-Promoted Iminium Ion−Alkyne Cyclizations in Alkaloid Construction 1996 ·Journal of the American Chemical Society ·Nan‐Horng Lin,Larry E. Overman,Michael H. Rabinowitz,Leslie A. Robinson,Matthew J. Sharp,Jeffery A. Zablocki	51
18	Enantioselective Total Syntheses of Allopumiliotoxins 267A, 323B‘, and 339A. Application of Iodide-Promoted Iminium Ion−Alkyne Cyclizations for Forming Allopumiliotoxin A Alkaloids 1996 ·Journal of the American Chemical Society ·Christian Caderas,Renee M. Lett,Larry E. Overman,Michael H. Rabinowitz,Leslie A. Robinson,Matthew J. Sharp,Jeffery A. Zablocki	45
19	The first enantioselective total syntheses of the allopumiliotoxin A alkaloids 267A and 339B 1992 ·The Journal of Organic Chemistry ·Steven W. Goldstein,Larry E. Overman,Michael H. Rabinowitz	69
20	A convenient and highly stereoselective synthesis of 4α-deuterio and -Tritio steroids catalyzed by Pd 1991 ·Tetrahedron Letters ·Michael H. Rabinowitz	6

About Michael H. Rabinowitz

Michael H. Rabinowitz is a scholar working on Cancer Research, Pharmacology and Organic Chemistry, having authored 29 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (8 papers), Neuropeptides and Animal Physiology (4 papers) and Metabolomics and Mass Spectrometry Studies (3 papers). The work is most often cited by research in Organic Chemistry (545 citations), Cancer Research (256 citations) and Biotechnology (73 citations). Michael H. Rabinowitz has collaborated with scholars based in United States, Belgium and United Kingdom. Frequent co-authors include Larry E. Overman, Paul A. Renhowe, Steven W. Goldstein, Hariharan Venkatesan, Mark D. Rosen, Leslie A. Robinson, Terrance D. Barrett, Nigel P. Shankley, Jeffery A. Zablocki and Matthew J. Sharp. Their work appears in journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact